Catalyst Pharmaceuticals Analyst Ratings
Catalyst Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/22/2023 | 84.93% | Cantor Fitzgerald | → $27 | Reiterates | Overweight → Overweight |
| 08/11/2023 | 84.93% | Cantor Fitzgerald | $25 → $27 | Maintains | Overweight |
| 08/11/2023 | 64.38% | HC Wainwright & Co. | → $24 | Reiterates | Buy → Buy |
| 07/21/2023 | 64.38% | HC Wainwright & Co. | → $24 | Reiterates | Buy → Buy |
| 06/21/2023 | 64.38% | Truist Securities | $22 → $24 | Maintains | Buy |
| 06/21/2023 | 71.23% | Cantor Fitzgerald | → $25 | Reiterates | Overweight → Overweight |
| 06/20/2023 | 64.38% | Truist Securities | $22 → $24 | Maintains | Buy |
| 05/12/2023 | 64.38% | HC Wainwright & Co. | → $24 | Reiterates | Buy → Buy |
| 03/20/2023 | 64.38% | HC Wainwright & Co. | → $24 | Reiterates | → Buy |
| 01/19/2023 | 50.68% | Truist Securities | $18 → $22 | Maintains | Buy |
| 12/21/2022 | 23.29% | Truist Securities | $17 → $18 | Maintains | Buy |
| 12/21/2022 | 64.38% | HC Wainwright & Co. | $18 → $24 | Maintains | Buy |
| 12/20/2022 | 36.99% | Piper Sandler | $18 → $20 | Maintains | Overweight |
| 08/24/2022 | 6.16% | Roth Capital | $10 → $15.5 | Downgrades | Buy → Neutral |
| 08/11/2022 | 16.44% | Truist Securities | $12 → $17 | Maintains | Buy |
| 08/11/2022 | 23.29% | HC Wainwright & Co. | $12 → $18 | Maintains | Buy |
| 02/08/2022 | -17.81% | HC Wainwright & Co. | $9 → $12 | Maintains | Buy |
| 03/18/2021 | -52.05% | Roth Capital | $6.5 → $7 | Maintains | Buy |
| 08/12/2020 | -45.21% | Truist Securities | $10 → $8 | Maintains | Buy |
| 05/13/2020 | -31.51% | SunTrust Robinson Humphrey | $11 → $10 | Maintains | Buy |
| 02/14/2020 | -17.81% | Cantor Fitzgerald | $11 → $12 | Reiterates | → Overweight |
| 12/13/2018 | -48.63% | Piper Sandler | $5 → $7.5 | Maintains | Overweight |
| 11/29/2018 | -45.21% | Cantor Fitzgerald | → $8 | Reiterates | → Overweight |
| 09/21/2018 | -45.21% | Cantor Fitzgerald | → $8 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月22日 | 84.93% | 康託·菲茨傑拉德 | →$27 | 重申 | 超重→超重 |
| 2023年08月11日 | 84.93% | 康託·菲茨傑拉德 | $25→$27 | 維護 | 超重 |
| 2023年08月11日 | 64.38% | HC Wainwright公司 | →$24 | 重申 | 購買→購買 |
| 07/21/2023 | 64.38% | HC Wainwright公司 | →$24 | 重申 | 購買→購買 |
| 2023年6月21日 | 64.38% | Truist證券 | $22→$24 | 維護 | 買 |
| 2023年6月21日 | 71.23% | 康託·菲茨傑拉德 | →$25 | 重申 | 超重→超重 |
| 06/20/2023 | 64.38% | Truist證券 | $22→$24 | 維護 | 買 |
| 2023年05月12日 | 64.38% | HC Wainwright公司 | →$24 | 重申 | 購買→購買 |
| 03/20/2023 | 64.38% | HC Wainwright公司 | →$24 | 重申 | →購買 |
| 2023年1月19日 | 50.68% | Truist證券 | $18→$22 | 維護 | 買 |
| 2022年12月21日 | 23.29% | Truist證券 | $17→$18 | 維護 | 買 |
| 2022年12月21日 | 64.38% | HC Wainwright公司 | $18→$24 | 維護 | 買 |
| 12/20/2022 | 36.99% | 派珀·桑德勒 | $18→$20 | 維護 | 超重 |
| 2022年08月24日 | 6.16% | 羅斯資本 | $10→$15.5 | 評級下調 | 購買→中性 |
| 2022年08月11日 | 16.44% | Truist證券 | $12→$17 | 維護 | 買 |
| 2022年08月11日 | 23.29% | HC Wainwright公司 | $12→$18 | 維護 | 買 |
| 02/08/2022 | -17.81% | HC Wainwright公司 | $9→$12 | 維護 | 買 |
| 03/18/2021 | -52.05% | 羅斯資本 | $6.5→$7 | 維護 | 買 |
| 2020年08月12日 | -45.21% | Truist證券 | $10→$8 | 維護 | 買 |
| 2020/05/13 | -31.51% | SunTrust Robinson Humphrey | $11→$10 | 維護 | 買 |
| 02/14/2020 | -17.81% | 康託·菲茨傑拉德 | $11→$12 | 重申 | →超重 |
| 2018年12月13日 | -48.63% | 派珀·桑德勒 | $5→$7.5 | 維護 | 超重 |
| 2018年11月29日 | -45.21% | 康託·菲茨傑拉德 | →$8 | 重申 | →超重 |
| 2018年09月21日 | -45.21% | 康託·菲茨傑拉德 | →$8 | 開始承保 | →超重 |
What is the target price for Catalyst Pharmaceuticals (CPRX)?
催化劑製藥(CPRX)的目標價是多少？
The latest price target for Catalyst Pharmaceuticals (NASDAQ: CPRX) was reported by Cantor Fitzgerald on August 22, 2023. The analyst firm set a price target for $27.00 expecting CPRX to rise to within 12 months (a possible 84.93% upside). 14 analyst firms have reported ratings in the last year.
坎託·菲茨傑拉德於2023年8月22日報道了催化劑製藥公司(納斯達克代碼：CPRX)的最新目標價。這家分析公司將目標價定為27美元，預計CPRX將在12個月內升至(可能上漲84.93%)。過去一年，有14家分析公司公佈了評級。
What is the most recent analyst rating for Catalyst Pharmaceuticals (CPRX)?
分析師對催化劑製藥公司(CPRX)的最新評級是多少？
The latest analyst rating for Catalyst Pharmaceuticals (NASDAQ: CPRX) was provided by Cantor Fitzgerald, and Catalyst Pharmaceuticals reiterated their overweight rating.
分析師對Catalyst PharmPharmticals(納斯達克代碼：CPRX)的最新評級由坎託·菲茨傑拉德提供，Catalyst PharmPharmticals重申其增持評級。
When is the next analyst rating going to be posted or updated for Catalyst Pharmaceuticals (CPRX)?
Catalyst PharmPharmticals(CPRX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Catalyst Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Catalyst Pharmaceuticals was filed on August 22, 2023 so you should expect the next rating to be made available sometime around August 22, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Catalyst PharmPharmticals的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Catalyst PharmPharmticals的上一次評級是在2023年8月22日提交的，因此您應該預計下一次評級將在2024年8月22日左右提供。
Is the Analyst Rating Catalyst Pharmaceuticals (CPRX) correct?
分析師對Catalyst PharmPharmticals(CPRX)的評級正確嗎？
While ratings are subjective and will change, the latest Catalyst Pharmaceuticals (CPRX) rating was a reiterated with a price target of $0.00 to $27.00. The current price Catalyst Pharmaceuticals (CPRX) is trading at is $14.60, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Catalyst PharmPharmticals(CPRX)評級被重申，目標價在0.00美元至27.00美元之間。Catalyst PharmPharmticals(CPRX)目前的交易價格為14.60美元，在分析師的預測範圍內。